Facebook
Google+
http://www.inovotion.com/publications/newsletter-2/newsletter-december-2019">
Twitter
LinkedIn

Newsletter Dec. 2019

Inovotion is showcasing its technology via the NC3Rs’ CRACK IT Solutions partnering programme.

Inovotion is showcasing its technology via the NC3Rs’ CRACK IT Solutions partnering programme.

Funding is available to focus on immuno-oncology drug screening, and aims to streamline early in vivo efficacy and toxicity evaluations using Inovotion’s model instead of mice (click here to learn more). The CRACK-IT Solutions programme allows academics and SMEs to showcase their 3Rs Solutions to the wider scientific community, to identify new partners and customers to use, develop and validate the technology. It provides a gateway for industry and others to scan for new strategically-relevant approaches to minimize animal suffering. In a previous CRACK IT Solution, Inovotion had partnered with AstraZeneca to test the utility of a chick embryo model to replace mouse xenograft studies in some Antibody-Drug Conjugates (ADC) developments (Download publication).

Learn more

Jean Viallet, INOVOTION’s CEO and founder, invited to testify on technology transfer, met Frédérique Vidal, French Minister for Advanced Education, Research and Innovation

Inovotion is a true success story and a world reference in accelerating preclinical studies. Jean Viallet, Inovotion’s CSO/CEO, has been invited to testify on technology transfer and met with Frederique Vidal, French Minister for Advanced Education, Research and Innovation during her visit to launch the #DeepTechTour in Grenoble. An exciting discussion and a really nice opportunity to share our experience, make proposals, and set up links.

Chick Embryo Chorioallantoic Membrane: a suitable and easy-to-use model for Photodynamic Therapies. An article from the University of Coimbra

ACS Omega 2019, 4, 17, 17244-17250

Publication Date:October 9, 2019

Ring-Fused Diphenylchlorins as Potent Photosensitizers for Photodynamic Therapy Applications: In Vitro Tumor Cell Biology and in Vivo Chick Embryo Chorioallantoic Membrane Studies

Bruno F. O. Nascimento,† Mafalda Laranjo,‡, Nelson A. M. Pereira†, João Dias-Ferreira ‡ Marta Piñeiro † Maria Filomena Botelho,‡ and Teresa M. V. D. Pinho e Melo*,††

CQC and Department of Chemistry, University of Coimbra, 3004-535 Coimbra, Portugal

‡ Biophysics Institute and Institute for Clinical and Biomedical Research (iCBR), area of Environment Genetics and Oncobiology(CIMAGO), Faculty of Medicine and CNC.IBILI Consortium, University of Coimbra, 3004-548 Coimbra, Portugal

New standardized cell lines

We continuously expand our library of validated cell lines on our model. Our catalog currently includes 50 cell lines and 17 reference compounds

A few of our newly validated cell lines

- MEL202 Uveal sarcoma

- 92.1 Uveal sarcoma

- H1373 Adenocarcinoma

Validated cell lines and compounds

FAQ: Is the chicken embryo model considered animal testing? Do you need to address ethical regulations to perform studies on the chicken embryo model?

The European Directive 2010/63/EU on the protection of animals used for scientific purposes and French Regulations (Code Rural R214-89 to R214-137, last modified in 2013) covers the use of chicken embryos starting at Day 18 of development (E18). Thus, there are no ethical constraints for us, because our studies are stopped at Day 18.

Concerning US regulation, according to the NIH, avian organisms are considered to be “live vertebrate animals” only after hatching. As such, the use of chicken embryos does not need to be reviewed or approved by institutional animal care and use committees.

Frequently asked questions

Where to meet us?

Every year, we attend dozens of events all over the world. These are opportunities to discuss your projects and our latest developments

PREDICT: Tumor Model - London - Dec 4-6

Première rencontre D2ONCO - Lyon - Dec 4

Cancer Metastasis - Seefeld in Tirol - Dec 11-14

Request a meeting

Who we are

Optimizing your preclinical and discovery studies is of prime importance, and INOVOTION has developed a solution based on its unique and cutting-edge in vivo technology.

As a Contract Research Organization (CRO) dedicated to in vivo evaluation for Drug Discovery mainly in oncology, INOVOTION is a sought-after partner for Pharma and Biotech companies as well as academic labs all over the world.

Our main missions are to:

  • Help you find the best candidate anti-cancer treatment
  • Detect the first in vivo toxicity effects of your candidate compounds
  • Improve productivity and Return-On-Investment of your preclinical and Drug Discovery process by maximizing your lead optimization phase

Accelerate the overall Drug Discovery process to answer unmet medical needs in oncology.

Any questions about Inovotion's technology? Call us or check out our F.A.Q.!

INOVOTION SA
HQ & Lab Facilities

+33 475 549 512

5 Avenue du Grand Sablon
38700 La Tronche
France

INOVOTION Inc.

185 Alewife Brook Parkway, Suite 210
Cambridge, MA 02138, USA

Facebook
Google+
http://www.inovotion.com/publications/newsletter-2/newsletter-december-2019">
Twitter
LinkedIn

Register for our Newsletter